
    
      Primary Objective:

      Â·The primary aim of this study is to assess the response rate of patients with previously
      treated colorectal cancer (CRC) Number of Subjects: 31

      Study Population:

      Subjects with metastatic, CRC who have failed a first-line chemotherapeutic regimen
      containing oxaliplatin and a fluoropyrimidine, and who have not previously received
      irinotecan or cetuximab for treatment of CRC.

      Test Product, Dose and Mode of Administration, Duration of Treatment:

      Cetuximab administered at an initial dose of 500 mg/m2 intravenously (IV) over 120 minutes,
      followed by 500 mg/m2 every 2 weeks IV over 60 minutes.

      Reference Therapy, Dose and Mode of Administration, Duration of Treatment: Irinotecan
      administered at a dose of 150a or 180 mg/m2 IV over 60 minutes every two weeks.
    
  